{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T23:06:21Z","timestamp":1791932781151,"version":"4.3.4"},"reference-count":79,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T00:00:00Z","timestamp":1758067200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002973","name":"Daiichi-Sankyo","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002973","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002336","name":"Daiichi Sankyo Co Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.critrevonc.2025.104951","type":"journal-article","created":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T16:40:17Z","timestamp":1757781617000},"page":"104951","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Tenosynovial giant cell tumor (TGCT): Mechanisms and advances in targeted treatments"],"prefix":"10.1016","volume":"216","author":[{"given":"Hairong","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nong","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaoming","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohui","family":"Niu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.critrevonc.2025.104951_bib1","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1038\/s41379-018-0129-0","article-title":"Malignant tenosynovial giant cell tumor: the true \"synovial sarcoma?\" a clinicopathologic, immunohistochemical, and molecular cytogenetic study of 10 cases, supporting origin from synoviocytes","volume":"32","author":"Al-Ibraheemi","year":"2019","journal-title":"Mod. Pathol."},{"issue":"5","key":"10.1016\/j.critrevonc.2025.104951_bib2","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1111\/j.1365-2559.2005.01959.x","article-title":"Rheumatoid arthritis and pigmented villonodular synovitis: comparative analysis of cell polyploidy, cell cycle phases and expression of macrophage and fibroblast markers in proliferating synovial cells","volume":"46","author":"Berger","year":"2005","journal-title":"Histopathology"},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104951_bib3","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1093\/annonc\/mdy129","article-title":"Complete response to CSF1R inhibitor in a translocation variant of teno-synovial giant cell tumor without genomic alteration of the CSF1 gene","volume":"29","author":"Brahmi","year":"2018","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104951_bib4","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s40425-017-0257-y","article-title":"Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy","volume":"5","author":"Cannarile","year":"2017","journal-title":"J. Immunother. Cancer"},{"issue":"23","key":"10.1016\/j.critrevonc.2025.104951_bib5","doi-asserted-by":"crossref","first-page":"10573","DOI":"10.7150\/thno.48666","article-title":"Cadherin-11 cooperates with inflammatory factors to promote the migration and invasion of fibroblast-like synoviocytes in pigmented villonodular synovitis","volume":"10","author":"Cao","year":"2020","journal-title":"Theranostics"},{"key":"10.1016\/j.critrevonc.2025.104951_bib6","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.ejca.2020.09.038","article-title":"Long-term clinical activity, safety and patient-reported quality of life for emactuzumab-treated patients with diffuse-type tenosynovial giant-cell tumour","volume":"141","author":"Cassier","year":"2020","journal-title":"Eur. J. Cancer"},{"issue":"8","key":"10.1016\/j.critrevonc.2025.104951_bib7","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1002\/jor.25216","article-title":"Neoplastic synovial lining cells that coexpress podoplanin and CD90 overproduce CSF-1, driving tenosynovial giant cell tumor","volume":"40","author":"Chandler","year":"2022","journal-title":"J. Orthop. Res"},{"key":"10.1016\/j.critrevonc.2025.104951_bib8","article-title":"Cancer de la gaine des tendons","author":"Chassaignac","year":"1852","journal-title":"Gaz. Des. H. \u00f4pitaux Civ. Et. Mil."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104951_bib9","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1186\/s13018-023-04279-2","article-title":"Identification of potential diagnostic biomarkers for tenosynovial giant cell tumour by integrating microarray and single-cell RNA sequencing data","volume":"18","author":"Chen","year":"2023","journal-title":"J. Orthop. Surg. Res"},{"key":"10.1016\/j.critrevonc.2025.104951_bib10","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.633796","article-title":"Triggering receptor expressed on myeloid Cells-2 (TREM2) interacts with Colony-Stimulating factor 1 receptor (CSF1R) but is not necessary for CSF1\/CSF1R-Mediated microglial survival","volume":"12","author":"Cheng","year":"2021","journal-title":"Front Immunol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104951_bib11","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.coi.2005.11.006","article-title":"Colony-stimulating factor-1 in immunity and inflammation","volume":"18","author":"Chitu","year":"2006","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.critrevonc.2025.104951_bib12","unstructured":"ClinicalTrials.gov, 2024. Study of Emactuzumab for Tenosynovial Giant Cell Tumor (TGCT) (TANGENT). ClinicalTrials.gov."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104951_bib13","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1007\/s11999-012-2589-8","article-title":"Does combined open and arthroscopic synovectomy for diffuse PVNS of the knee improve recurrence rates?","volume":"471","author":"Colman","year":"2013","journal-title":"Clin. Orthop. Relat. Res"},{"issue":"12","key":"10.1016\/j.critrevonc.2025.104951_bib14","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1177\/43.12.8537635","article-title":"Human osteoclast and giant cell differentiation: the apparent switch from nonspecific esterase to tartrate resistant acid phosphatase activity coincides with the in situ expression of osteopontin mRNA","volume":"43","author":"Connor","year":"1995","journal-title":"J. Histochem Cytochem"},{"issue":"8","key":"10.1016\/j.critrevonc.2025.104951_bib15","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1007\/s00256-020-03694-4","article-title":"Limited usefulness of classic MR findings in the diagnosis of tenosynovial giant cell tumor","volume":"50","author":"Crim","year":"2021","journal-title":"Skelet. Radio."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104951_bib16","first-page":"1383","article-title":"Multinucleated cells in pigmented villonodular synovitis and giant cell tumor of tendon sheath express features of osteoclasts","volume":"150","author":"Darling","year":"1997","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.critrevonc.2025.104951_bib17","series-title":"Tenosynovial Giant Cell Tumour","first-page":"133","article-title":"World health organization (WHO) classification of soft tissue and bone tumours","author":"De Saint Aubain Somerhausen","year":"2020"},{"issue":"16","key":"10.1016\/j.critrevonc.2025.104951_bib18","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.2217\/fon-2023-0363","article-title":"Real-world drug utilization and treatment patterns in patients with tenosynovial giant cell tumors in the USA","volume":"20","author":"Dharmani","year":"2024","journal-title":"Future Oncol."},{"issue":"10","key":"10.1016\/j.critrevonc.2025.104951_bib19","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.3899\/jrheum.160816","article-title":"Tenosynovial giant cell tumor: incidence, prevalence, patient characteristics, and recurrence. A Registry-based cohort study in Denmark","volume":"44","author":"Ehrenstein","year":"2017","journal-title":"J. Rheuma"},{"issue":"11","key":"10.1016\/j.critrevonc.2025.104951_bib20","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/j.autrev.2010.07.001","article-title":"Molecular pathways involved in synovial cell inflammation and tumoral proliferation in diffuse pigmented villonodular synovitis","volume":"9","author":"Fiocco","year":"2010","journal-title":"Autoimmun. Rev."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104951_bib21","first-page":"268-274","article-title":"Intra-articular treatment with the TNF-alpha antagonist, etanercept, in severe diffuse pigmented villonodular synovitis of the knee","volume":"58","author":"Fiocco","year":"2006","journal-title":"Reumatismo"},{"issue":"8","key":"10.1016\/j.critrevonc.2025.104951_bib22","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1158\/1535-7163.MCT-20-0591","article-title":"CSF1\/CSF1R signaling inhibitor pexidartinib (PLX3397) reprograms Tumor-Associated macrophages and stimulates T-cell infiltration in the sarcoma microenvironment","volume":"20","author":"Fujiwara","year":"2021","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.critrevonc.2025.104951_bib23","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.1012527","article-title":"Expanding the molecular spectrum of tenosynovial giant cell tumors","volume":"12","author":"Gauduchon","year":"2022","journal-title":"Front Oncol."},{"issue":"10445","key":"10.1016\/j.critrevonc.2025.104951_bib24","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1016\/S0140-6736(24)00885-7","article-title":"Vimseltinib versus placebo for tenosynovial giant cell tumour (MOTION): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"403","author":"Gelderblom","year":"2024","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.critrevonc.2025.104951_bib25","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/S1470-2045(18)30143-8","article-title":"Nilotinib in locally advanced pigmented villonodular synovitis: a multicentre, open-label, single-arm, phase 2 trial","volume":"19","author":"Gelderblom","year":"2018","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2025.104951_bib26","doi-asserted-by":"crossref","first-page":"S1233","DOI":"10.1016\/j.annonc.2021.08.275","article-title":"1821P safety and preliminary efficacy of vimseltinib in tenosynovial giant cell tumor (TGCT)","volume":"32","author":"Gelderblom","year":"2021","journal-title":"Ann. Oncol."},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104951_bib27","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1002\/cncr.33312","article-title":"Long-term outcomes of pexidartinib in tenosynovial giant cell tumors","volume":"127","author":"Gelderblom","year":"2021","journal-title":"Cancer"},{"issue":"1s","key":"10.1016\/j.critrevonc.2025.104951_bib28","doi-asserted-by":"crossref","first-page":"S91","DOI":"10.1016\/j.otsr.2016.11.002","article-title":"Localized and diffuse forms of tenosynovial giant cell tumor (formerly giant cell tumor of the tendon sheath and pigmented villonodular synovitis)","volume":"103","author":"Gouin","year":"2017","journal-title":"Orthop. Trauma. Surg. Res"},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104951_bib29","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1038\/s41416-022-02096-8","article-title":"The role of PPAR\u03b3 in prostate cancer development and progression","volume":"128","author":"Hartley","year":"2023","journal-title":"Br. J. Cancer"},{"issue":"11","key":"10.1016\/j.critrevonc.2025.104951_bib30","first-page":"e20.00028","article-title":"Management of tenosynovial giant cell tumor: a neoplastic and inflammatory disease","volume":"4","author":"Healey","year":"2020","journal-title":"J. Am. Acad. Orthop. Surg. Glob. Res Rev."},{"key":"10.1016\/j.critrevonc.2025.104951_bib31","series-title":"Pexidartinib use in patients with tenosynovial giant cell tumor: an analysis of the phase 3 randomized ENLIVEN clinical trial according to surgical history","author":"Healey","year":"2024"},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104951_bib32","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1002\/gcc.22807","article-title":"Detection of CSF1 rearrangements deleting the 3\u2032 UTR in tenosynovial giant cell tumors","volume":"59","author":"Ho","year":"2020","journal-title":"Genes Chromosomes Cancer"},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104951_bib33","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1002\/JLB.MR0519-143R","article-title":"Phenotypic impacts of CSF1R deficiencies in humans and model organisms","volume":"107","author":"Hume","year":"2020","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.critrevonc.2025.104951_bib34","first-page":"731","article-title":"Pigmented villonodular synovitis, bursitis and tenosynovitis","volume":"31","author":"Jaffe","year":"1941","journal-title":"Arch. Pathol."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104951_bib35","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1007\/s00256-022-04170-x","article-title":"Tenosynovial giant cell tumors of digits: MRI differentiation between localized types and diffuse types with pathology correlation","volume":"52","author":"Jeong","year":"2023","journal-title":"Skelet. Radio."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104951_bib36","first-page":"93","article-title":"Tenosynovial giant cell tumor","volume":"62","author":"Kager","year":"2022","journal-title":"Folia Med Cracov"},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104951_bib37","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1136\/ard.2004.025692","article-title":"Tumour necrosis factor alpha blockade in treatment resistant pigmented villonodular synovitis","volume":"64","author":"Kroot","year":"2005","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.critrevonc.2025.104951_bib38","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/j.biopha.2018.04.046","article-title":"Recent advances in colony stimulating factor-1 receptor\/c-FMS as an emerging target for various therapeutic implications","volume":"103","author":"Kumari","year":"2018","journal-title":"Biomed. Pharm."},{"issue":"16","key":"10.1016\/j.critrevonc.2025.104951_bib39","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1007\/s40265-019-01210-0","article-title":"Pexidartinib: first approval","volume":"79","author":"Lamb","year":"2019","journal-title":"Drugs"},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104951_bib40","doi-asserted-by":"crossref","first-page":"e535","DOI":"10.1093\/oncolo\/oyad282","article-title":"Real-World patient experience of pexidartinib for tenosynovial Giant-Cell tumor","volume":"29","author":"Lin","year":"2024","journal-title":"Oncologist"},{"key":"10.1016\/j.critrevonc.2025.104951_bib41","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.3389\/fimmu.2019.02019","article-title":"Function of CSF1 and IL34 in macrophage homeostasis, inflammation, and cancer","volume":"10","author":"Lin","year":"2019","journal-title":"Front Immunol."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104951_bib42","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1111\/his.13744","article-title":"Does CSF1 overexpression or rearrangement influence biological behaviour in tenosynovial giant cell tumours of the knee?","volume":"74","author":"Mastboom","year":"2019","journal-title":"Histopathology"},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104951_bib43","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1080\/17453674.2017.1361126","article-title":"Higher incidence rates than previously known in tenosynovial giant cell tumors","volume":"88","author":"Mastboom","year":"2017","journal-title":"Acta Orthop."},{"key":"10.1016\/j.critrevonc.2025.104951_bib44","unstructured":"Merck, 2024. Pimicotinib Significantly Improved Outcomes for Patients with Tenosynovial Giant Cell Tumor in a Global Phase III Trial."},{"issue":"8","key":"10.1016\/j.critrevonc.2025.104951_bib45","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1038\/s12276-020-0484-z","article-title":"The M-CSF receptor in osteoclasts and beyond","volume":"52","author":"Mun","year":"2020","journal-title":"Exp. Mol. Med"},{"issue":"5","key":"10.1016\/j.critrevonc.2025.104951_bib46","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1136\/annrheumdis-2013-204589","article-title":"Efficacy of intra-articular bevacizumab for relapsing diffuse-type giant cell tumour","volume":"73","author":"Nissen","year":"2014","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.critrevonc.2025.104951_bib47","first-page":"1","article-title":"MANEUVER: a phase III study of pimicotinib to assess efficacy and safety in tenosynovial giant cell tumor patients","author":"Niu","year":"2024","journal-title":"Future Oncol."},{"key":"10.1016\/j.critrevonc.2025.104951_bib48","first-page":"26","article-title":"Cytokine and matrix metalloproteinase expression in pigmented villonodular synovitis May mediate bone and cartilage destruction","volume":"18","author":"O'Keefe","year":"1998","journal-title":"Iowa Orthop. J."},{"issue":"7","key":"10.1016\/j.critrevonc.2025.104951_bib49","doi-asserted-by":"crossref","first-page":"5361","DOI":"10.1007\/s13277-015-3197-5","article-title":"Expression of colony-stimulating factor 1 is associated with occurrence of osteochondral change in pigmented villonodular synovitis","volume":"36","author":"Ota","year":"2015","journal-title":"Tumour Biol."},{"key":"10.1016\/j.critrevonc.2025.104951_bib50","doi-asserted-by":"crossref","DOI":"10.1007\/s40487-024-00298-z","article-title":"Pexidartinib upfront in a case of tenosynovial giant cell tumor: proof of concept for a treatment paradigm shift","author":"Palmerini","year":"2024","journal-title":"Oncol. Ther."},{"issue":"5","key":"10.1016\/j.critrevonc.2025.104951_bib51","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.3892\/ijo.2014.2326","article-title":"Novel CSF1-S100A10 fusion gene and CSF1 transcript identified by RNA sequencing in tenosynovial giant cell tumors","volume":"44","author":"Panagopoulos","year":"2014","journal-title":"Int J. Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104951_bib52","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1016\/j.knee.2017.03.011","article-title":"Pigmented villonodular synovitis of the knee: a retrospective analysis of 214 cases at a UK tertiary referral centre","volume":"24","author":"Patel","year":"2017","journal-title":"Knee"},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104951_bib53","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1302\/2058-5241.5.200005","article-title":"Open versus arthroscopic surgery for diffuse tenosynovial giant-cell tumours of the knee: a systematic review","volume":"5","author":"Quaresma","year":"2020","journal-title":"EFORT Open Rev."},{"key":"10.1016\/j.critrevonc.2025.104951_bib54","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.820046","article-title":"Update on tenosynovial giant cell tumor, an inflammatory arthritis with neoplastic features","volume":"13","author":"Robert","year":"2022","journal-title":"Front Immunol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104951_bib55","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1101\/gad.948702","article-title":"C\/EBPalpha induces adipogenesis through PPARgamma: a unified pathway","volume":"16","author":"Rosen","year":"2002","journal-title":"Genes Dev."},{"key":"10.1016\/j.critrevonc.2025.104951_bib56","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.ejca.2022.06.028","article-title":"Long-term follow-up of nilotinib in patients with advanced tenosynovial giant cell tumours: Long-term follow-up of nilotinib in TGCT","volume":"173","author":"Spierenburg","year":"2022","journal-title":"Eur. J. Cancer"},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104951_bib57","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1080\/14728222.2022.2067040","article-title":"Tenosynovial giant cell tumors (TGCT): molecular biology, drug targets and non-surgical pharmacological approaches","volume":"26","author":"Spierenburg","year":"2022","journal-title":"Expert Opin. Ther. Targets"},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104951_bib58","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15030941","article-title":"One-Stage synovectomies result in improved Short-Term outcomes compared to Two-Stage synovectomies of Diffuse-Type tenosynovial giant cell tumor (D-TGCT) of the knee: a multicenter, retrospective, cohort study","volume":"15","author":"Spierenburg","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.critrevonc.2025.104951_bib59","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2022.102491","article-title":"Best clinical management of tenosynovial giant cell tumour (TGCT): a consensus paper from the community of experts","volume":"112","author":"Stacchiotti","year":"2023","journal-title":"Cancer Treat. Rev."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104951_bib60","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/(SICI)1098-2795(199701)46:1<4::AID-MRD2>3.0.CO;2-V","article-title":"Biology and action of colony--stimulating factor-1","volume":"46","author":"Stanley","year":"1997","journal-title":"Mol. Reprod. Dev."},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104951_bib61","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a021857","article-title":"CSF-1 receptor signaling in myeloid cells","volume":"6","author":"Stanley","year":"2014","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"10.1016\/j.critrevonc.2025.104951_bib62","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.900010","article-title":"Randomized placebo-controlled double-blind phase II study of zaltoprofen for patients with diffuse-type and unresectable localized tenosynovial giant cell tumors: the REALIZE study","volume":"12","author":"Takeuchi","year":"2022","journal-title":"Front Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2025.104951_bib63","first-page":"2169","article-title":"Complete necrosis of a giant cell tumor with high expression of PPAR\u03b3: a case report","volume":"33","author":"Takeuchi","year":"2013","journal-title":"Anticancer Res"},{"issue":"10197","key":"10.1016\/j.critrevonc.2025.104951_bib64","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/S0140-6736(19)30764-0","article-title":"Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial","volume":"394","author":"Tap","year":"2019","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104951_bib65","doi-asserted-by":"crossref","first-page":"239","DOI":"10.3233\/TUB-220005","article-title":"Role of colony-stimulating factor 1 in the neoplastic process of tenosynovial giant cell tumor","volume":"44","author":"Tap","year":"2022","journal-title":"Tumour Biol."},{"issue":"10","key":"10.1016\/j.critrevonc.2025.104951_bib66","doi-asserted-by":"crossref","first-page":"593","DOI":"10.2217\/fon-2023-0238","article-title":"The MOTION study: a randomized, phase III study of vimseltinib for the treatment of tenosynovial giant cell tumor","volume":"20","author":"Tap","year":"2024","journal-title":"Future Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2025.104951_bib67","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1056\/NEJMoa1411366","article-title":"Structure-Guided blockade of CSF1R kinase in tenosynovial Giant-Cell tumor","volume":"373","author":"Tap","year":"2015","journal-title":"N. Engl. J. Med"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104951_bib68","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1002\/path.2937","article-title":"Osteoclast formation and function in pigmented villonodular synovitis","volume":"225","author":"Taylor","year":"2011","journal-title":"J. Pathol."},{"key":"10.1016\/j.critrevonc.2025.104951_bib69","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.humpath.2021.05.010","article-title":"RNAscope CSF1 chromogenic in situ hybridization: a potentially useful tool in the differential diagnosis of tenosynovial giant cell tumors","volume":"115","author":"Thangaiah","year":"2021","journal-title":"Hum. Pathol."},{"issue":"12","key":"10.1016\/j.critrevonc.2025.104951_bib70","doi-asserted-by":"crossref","first-page":"3276","DOI":"10.1002\/ijc.32421","article-title":"Massively parallel sequencing of tenosynovial giant cell tumors reveals novel CSF1 fusion transcripts and novel somatic CBL mutations","volume":"145","author":"Tsuda","year":"2019","journal-title":"Int J. Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104951_bib71","first-page":"110","article-title":"Expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in pigmented villonodular synovitis suggests their potential role for joint destruction","volume":"31","author":"Uchibori","year":"2004","journal-title":"J. Rheuma"},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104951_bib72","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1002\/1097-0142(19860215)57:4<875::AID-CNCR2820570432>3.0.CO;2-Y","article-title":"Giant cell tumor of the tendon sheath (nodular tenosynovitis). a study of 207 cases to compare the large joint group with the common digit group","volume":"57","author":"Ushijima","year":"1986","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104951_bib73","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1002\/jso.23220","article-title":"A multidisciplinary approach to giant cell tumors of tendon sheath and synovium--a critical appraisal of literature and treatment proposal","volume":"107","author":"van der Heijden","year":"2013","journal-title":"J. Surg. Oncol."},{"issue":"22","key":"10.1016\/j.critrevonc.2025.104951_bib74","doi-asserted-by":"crossref","first-page":"4934","DOI":"10.1158\/1078-0432.CCR-22-1898","article-title":"Interactions in CSF1-Driven tenosynovial giant cell tumors","volume":"28","author":"van IJzendoorn","year":"2022","journal-title":"Clin. Cancer Res"},{"issue":"10","key":"10.1016\/j.critrevonc.2025.104951_bib75","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.2217\/fon.13.124","article-title":"Pigmented villonodular synovitis: current concepts about diagnosis and management","volume":"9","author":"Verspoor","year":"2013","journal-title":"Future Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104951_bib76","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-51211-y","article-title":"Long-term efficacy of imatinib mesylate in patients with advanced tenosynovial giant cell tumor","volume":"9","author":"Verspoor","year":"2019","journal-title":"Sci. Rep."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104951_bib77","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1073\/pnas.0507321103","article-title":"A landscape effect in tenosynovial giant-cell tumor from activation of CSF1 expression by a translocation in a minority of tumor cells","volume":"103","author":"West","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104951_bib78","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1620\/tjem.248.87","article-title":"Expression profiling of Receptor-Activator of nuclear Factor-Kappa b ligand in soft tissue tumors","volume":"248","author":"Yamagishi","year":"2019","journal-title":"Tohoku J. Exp. Med"},{"key":"10.1016\/j.critrevonc.2025.104951_bib79","article-title":"Gene expression profiles analyzed using integrating RNA sequencing, and microarray reveals increased inflammatory response, proliferation, and osteoclastogenesis in pigmented villonodular synovitis","volume":"12","author":"Zhao","year":"2021","journal-title":"Front Immunol."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842825003397?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842825003397?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T06:27:38Z","timestamp":1773124058000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842825003397"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":79,"alternative-id":["S1040842825003397"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2025.104951","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tenosynovial giant cell tumor (TGCT): Mechanisms and advances in targeted treatments","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2025.104951","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"104951"}}